According to early data from a new clinical trial, adolescent and children patients treated with the drug Xolair were less likely to have severe allergic reactions when ingesting triggering foods than those treated with placebos.
Xolair, also known as the monoclonal antibody omalizumab, is currently on the market as an asthma treatment.
However, the National Institute of Allergy and Infectious Diseases-backed research could see Xolair’s approval as an injectable medication for food-based allergies.
“The major advantage of this medication is that it will cover more than one food and that it has been around for about two decades and we know its safety profile, which is pretty good,” said NIAID Chief of Allergy Dr. Alkis Togias.
